-
1
-
-
0036822286
-
An open study of B lymphocyte depletion in systemic lupus erythematosus
-
M.J. Leandro, J.C. Edwards, G. Cambridge, M.R. Ehrenstein, and D.A. Isenberg An open study of B lymphocyte depletion in systemic lupus erythematosus Arthritis & Rheumatism 46 2002 2673 2677
-
(2002)
Arthritis & Rheumatism
, vol.46
, pp. 2673-2677
-
-
Leandro, M.J.1
Edwards, J.C.2
Cambridge, G.3
Ehrenstein, M.R.4
Isenberg, D.A.5
-
2
-
-
13444252282
-
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial
-
P.P. Sfikakis, J.N. Boletis, and S. Lionaki Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial Arthritis & Rheumatism 52 2005 501 513
-
(2005)
Arthritis & Rheumatism
, vol.52
, pp. 501-513
-
-
Sfikakis, P.P.1
Boletis, J.N.2
Lionaki, S.3
-
3
-
-
4043179907
-
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
-
R.J. Looney, J.H. Anolik, and D. Campbell B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab Arthritis & Rheumatism 50 2004 2580 2589
-
(2004)
Arthritis & Rheumatism
, vol.50
, pp. 2580-2589
-
-
Looney, R.J.1
Anolik, J.H.2
Campbell, D.3
-
4
-
-
34247246405
-
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis
-
I. Gunnarsson, B. Sundelin, T. Jonsdottir, S.H. Jacobson, E.W. Henriksson, and R.F. van Vollenhoven Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis Arthritis & Rheumatism 56 2007 1263 1272
-
(2007)
Arthritis & Rheumatism
, vol.56
, pp. 1263-1272
-
-
Gunnarsson, I.1
Sundelin, B.2
Jonsdottir, T.3
Jacobson, S.H.4
Henriksson, E.W.5
Van Vollenhoven, R.F.6
-
5
-
-
39549108298
-
Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes, and predictors of response
-
T. Jonsdottir, I. Gunnarsson, A. Risselada, E.W. Henriksson, L. Klareskog, and R.F. van Vollenhoven Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response Annals of the Rheumatic Diseases 67 2008 330 334
-
(2008)
Annals of the Rheumatic Diseases
, vol.67
, pp. 330-334
-
-
Jonsdottir, T.1
Gunnarsson, I.2
Risselada, A.3
Henriksson, E.W.4
Klareskog, L.5
Van Vollenhoven, R.F.6
-
6
-
-
79955804762
-
Rituximab-treated membranous lupus nephritis: Clinical outcome and effects on electron dense deposits
-
T. Jonsdottir, B. Sundelin, E. Welin Henriksson, R.F. van Vollenhoven, and I. Gunnarsson Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits Annals of the Rheumatic Diseases 70 2011 1172 1173
-
(2011)
Annals of the Rheumatic Diseases
, vol.70
, pp. 1172-1173
-
-
Jonsdottir, T.1
Sundelin, B.2
Welin Henriksson, E.3
Van Vollenhoven, R.F.4
Gunnarsson, I.5
-
7
-
-
10844243750
-
Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone
-
R.F. van Vollenhoven, I. Gunnarsson, and E. Welin-Henriksson Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone Scandinavian Journal of Rheumatology 33 2004 423 427
-
(2004)
Scandinavian Journal of Rheumatology
, vol.33
, pp. 423-427
-
-
Van Vollenhoven, R.F.1
Gunnarsson, I.2
Welin-Henriksson, E.3
-
8
-
-
84876712988
-
Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response
-
T. Jonsdottir, A. Zickert, B. Sundelin, E.W. Henriksson, R.F. van Vollenhoven, and I. Gunnarsson Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response Rheumatology 52 2013 847 855
-
(2013)
Rheumatology
, vol.52
, pp. 847-855
-
-
Jonsdottir, T.1
Zickert, A.2
Sundelin, B.3
Henriksson, E.W.4
Van Vollenhoven, R.F.5
Gunnarsson, I.6
-
9
-
-
84866184129
-
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis the lupus nephritis assessment with rituximab study
-
B.H. Rovin, R. Furie, and K. Latinis Efficacy and safety of rituximab in patients with active proliferative lupus nephritis the lupus nephritis assessment with rituximab study Arthritis & Rheumatism 64 2012 1215 1226
-
(2012)
Arthritis & Rheumatism
, vol.64
, pp. 1215-1226
-
-
Rovin, B.H.1
Furie, R.2
Latinis, K.3
-
10
-
-
67650606765
-
Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases
-
M. Ramos-Casals, M.J. Soto, M.J. Cuadrado, and M.A. Khamashta Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases Lupus 18 2009 767 776
-
(2009)
Lupus
, vol.18
, pp. 767-776
-
-
Ramos-Casals, M.1
Soto, M.J.2
Cuadrado, M.J.3
Khamashta, M.A.4
-
11
-
-
28544449032
-
B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients
-
M.J. Leandro, G. Cambridge, J.C. Edwards, M.R. Ehrenstein, and D.A. Isenberg B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients Rheumatology 44 2005 1542 1545
-
(2005)
Rheumatology
, vol.44
, pp. 1542-1545
-
-
Leandro, M.J.1
Cambridge, G.2
Edwards, J.C.3
Ehrenstein, M.R.4
Isenberg, D.A.5
-
12
-
-
74849131972
-
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
-
J.T. Merrill, C.M. Neuwelt, and D.J. Wallace Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Arthritis & Rheumatism 62 2010 222 233
-
(2010)
Arthritis & Rheumatism
, vol.62
, pp. 222-233
-
-
Merrill, J.T.1
Neuwelt, C.M.2
Wallace, D.J.3
-
13
-
-
71049118062
-
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
-
R. Pepper, M. Griffith, and C. Kirwan Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids Nephrology Dialysis Transplantation 24 2009 3717 3723
-
(2009)
Nephrology Dialysis Transplantation
, vol.24
, pp. 3717-3723
-
-
Pepper, R.1
Griffith, M.2
Kirwan, C.3
-
14
-
-
84880243381
-
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
-
M.B. Condon, D. Ashby, and R.J. Pepper Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids Annals of the Rheumatic Diseases 72 2013 1280 1286
-
(2013)
Annals of the Rheumatic Diseases
, vol.72
, pp. 1280-1286
-
-
Condon, M.B.1
Ashby, D.2
Pepper, R.J.3
-
15
-
-
84857562039
-
Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: A steroid-sparing regimen
-
A.N. Ezeonyeji, and D.A. Isenberg Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen Rheumatology 51 2012 476 481
-
(2012)
Rheumatology
, vol.51
, pp. 476-481
-
-
Ezeonyeji, A.N.1
Isenberg, D.A.2
-
16
-
-
77957682858
-
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
-
J.T. Merrill, R. Burgos-Vargas, and R. Westhovens The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial Arthritis & Rheumatism 62 2010 3077 3087
-
(2010)
Arthritis & Rheumatism
, vol.62
, pp. 3077-3087
-
-
Merrill, J.T.1
Burgos-Vargas, R.2
Westhovens, R.3
-
17
-
-
78650632504
-
An assessment of disease flare in patients with systemic lupus erythematosus: A comparison of BILAG 2004 and the flare version of SELENA
-
D.A. Isenberg, E. Allen, and V. Farewell An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA Annals of the Rheumatic Diseases 70 2011 54 59
-
(2011)
Annals of the Rheumatic Diseases
, vol.70
, pp. 54-59
-
-
Isenberg, D.A.1
Allen, E.2
Farewell, V.3
-
18
-
-
84863756711
-
Efficacy and safety of abatacept over 12 Months in patients with lupus nephritis: Results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study
-
R. Furie, K. Nicholls, and T.T. Cheng Efficacy and safety of abatacept over 12 Months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study Arthritis & Rheumatism 63 2011 S962 S983
-
(2011)
Arthritis & Rheumatism
, vol.63
-
-
Furie, R.1
Nicholls, K.2
Cheng, T.T.3
-
19
-
-
84868126198
-
Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions
-
D. Wofsy, J.L. Hillson, and B. Diamond Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions Arthritis & Rheumatism 64 2012 3660 3665
-
(2012)
Arthritis & Rheumatism
, vol.64
, pp. 3660-3665
-
-
Wofsy, D.1
Hillson, J.L.2
Diamond, B.3
-
20
-
-
45349102050
-
Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index
-
M. Petri, N. Kasitanon, and S.S. Lee Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index Arthritis & Rheumatism 58 2008 1784 1788
-
(2008)
Arthritis & Rheumatism
, vol.58
, pp. 1784-1788
-
-
Petri, M.1
Kasitanon, N.2
Lee, S.S.3
-
21
-
-
45349106761
-
Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response
-
M. Petri, N. Kasitanon, and S. Singh Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response Arthritis & Rheumatism 58 2008 1789 1795
-
(2008)
Arthritis & Rheumatism
, vol.58
, pp. 1789-1795
-
-
Petri, M.1
Kasitanon, N.2
Singh, S.3
-
22
-
-
0028483990
-
Treatment of murine lupus with CTLA4Ig
-
B.K. Finck, P.S. Linsley, and D. Wofsy Treatment of murine lupus with CTLA4Ig Science 265 1994 1225 1227
-
(1994)
Science
, vol.265
, pp. 1225-1227
-
-
Finck, B.K.1
Linsley, P.S.2
Wofsy, D.3
-
23
-
-
77950238639
-
Monoclonal antibodies and fusion proteins and their complications: Targeting B cells in autoimmune diseases
-
S. Lee, and M. Ballow Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases The Journal of Allergy and Clinical Immunology 125 2010 814 820
-
(2010)
The Journal of Allergy and Clinical Immunology
, vol.125
, pp. 814-820
-
-
Lee, S.1
Ballow, M.2
-
24
-
-
0242495115
-
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
-
K.P. Baker, B.M. Edwards, and S.H. Main Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator Arthritis and Rheumatism 48 2003 3253 3265
-
(2003)
Arthritis and Rheumatism
, vol.48
, pp. 3253-3265
-
-
Baker, K.P.1
Edwards, B.M.2
Main, S.H.3
-
25
-
-
69749120918
-
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
-
D.J. Wallace, W. Stohl, and R.A. Furie A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus Arthritis and Rheumatism 61 2009 1168 1178
-
(2009)
Arthritis and Rheumatism
, vol.61
, pp. 1168-1178
-
-
Wallace, D.J.1
Stohl, W.2
Furie, R.A.3
-
26
-
-
84875947710
-
Belimumab for systemic lupus erythematosus: A practice-based view
-
I. Parodis, M. Axelsson, and I. Gunnarsson Belimumab for systemic lupus erythematosus: a practice-based view Lupus 22 2013 372 380
-
(2013)
Lupus
, vol.22
, pp. 372-380
-
-
Parodis, I.1
Axelsson, M.2
Gunnarsson, I.3
-
27
-
-
79952070370
-
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial
-
S.V. Navarra, R.M. Guzman, and A.E. Gallacher Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Lancet 377 2011 721 731
-
(2011)
Lancet
, vol.377
, pp. 721-731
-
-
Navarra, S.V.1
Guzman, R.M.2
Gallacher, A.E.3
-
28
-
-
82455198794
-
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
-
R. Furie, M. Petri, and O. Zamani A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Arthritis and Rheumatism 63 2011 3918 3930
-
(2011)
Arthritis and Rheumatism
, vol.63
, pp. 3918-3930
-
-
Furie, R.1
Petri, M.2
Zamani, O.3
-
30
-
-
84862002288
-
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
-
W. Stohl, F. Hiepe, and K.M. Latinis Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus Arthritis and Rheumatism 64 2012 2328 2337
-
(2012)
Arthritis and Rheumatism
, vol.64
, pp. 2328-2337
-
-
Stohl, W.1
Hiepe, F.2
Latinis, K.M.3
-
31
-
-
84867398973
-
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials
-
S. Manzi, J. Sanchez-Guerrero, and J.T. Merrill Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials Annals of the Rheumatic Diseases 71 2012 1833 1838
-
(2012)
Annals of the Rheumatic Diseases
, vol.71
, pp. 1833-1838
-
-
Manzi, S.1
Sanchez-Guerrero, J.2
Merrill, J.T.3
-
32
-
-
84863850571
-
Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response
-
R.F. van Vollenhoven, M.A. Petri, and R. Cervera Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response Annals of the Rheumatic Diseases 71 2012 1343 1349
-
(2012)
Annals of the Rheumatic Diseases
, vol.71
, pp. 1343-1349
-
-
Van Vollenhoven, R.F.1
Petri, M.A.2
Cervera, R.3
-
33
-
-
84871574493
-
Effect of belimumab treatment on renal outcomes: Results from the phase 3 belimumab clinical trials in patients with SLE
-
M.A. Dooley, F. Houssiau, and C. Aranow Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE Lupus 22 2013 63 72
-
(2013)
Lupus
, vol.22
, pp. 63-72
-
-
Dooley, M.A.1
Houssiau, F.2
Aranow, C.3
-
34
-
-
84897996554
-
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
-
V. Strand, R.A. Levy, and R. Cervera Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials Annals of the Rheumatic Diseases 2013
-
(2013)
Annals of the Rheumatic Diseases
-
-
Strand, V.1
Levy, R.A.2
Cervera, R.3
-
35
-
-
84872529430
-
Safety profile of belimumab: Pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus
-
D.J. Wallace, S. Navarra, and M.A. Petri Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus Lupus 22 2013 144 154
-
(2013)
Lupus
, vol.22
, pp. 144-154
-
-
Wallace, D.J.1
Navarra, S.2
Petri, M.A.3
-
36
-
-
84869072981
-
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus
-
J.T. Merrill, E.M. Ginzler, and D.J. Wallace Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus Arthritis & Rheumatism 64 2012 3364 3373
-
(2012)
Arthritis & Rheumatism
, vol.64
, pp. 3364-3373
-
-
Merrill, J.T.1
Ginzler, E.M.2
Wallace, D.J.3
-
37
-
-
84885332343
-
Trogocytosis of multiple B-cell surface markers by CD22-targeting with epratuzumab
-
E.A. Rossi, D.M. Goldenberg, R. Michel, D.L. Rossi, D.J. Wallace, and C.H. Chang Trogocytosis of multiple B-cell surface markers by CD22-targeting with epratuzumab Blood 2013
-
(2013)
Blood
-
-
Rossi, E.A.1
Goldenberg, D.M.2
Michel, R.3
Rossi, D.L.4
Wallace, D.J.5
Chang, C.H.6
-
38
-
-
84879502096
-
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
-
D.J. Wallace, C. Gordon, and V. Strand Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up Rheumatology 52 2013 1313 1322
-
(2013)
Rheumatology
, vol.52
, pp. 1313-1322
-
-
Wallace, D.J.1
Gordon, C.2
Strand, V.3
-
39
-
-
84889645482
-
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
-
D.J. Wallace, K. Kalunian, and M.A. Petri Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study Annals of the Rheumatic Diseases 2013
-
(2013)
Annals of the Rheumatic Diseases
-
-
Wallace, D.J.1
Kalunian, K.2
Petri, M.A.3
-
40
-
-
84881480273
-
Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors
-
M.C. Genovese, R.M. Fleischmann, and M. Greenwald Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors Annals of the Rheumatic Diseases 2012
-
(2012)
Annals of the Rheumatic Diseases
-
-
Genovese, M.C.1
Fleischmann, R.M.2
Greenwald, M.3
-
41
-
-
84875715149
-
Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: A phase II, randomized, placebo-controlled trial
-
M.C. Genovese, S. Bojin, and I.M. Biagini Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial Arthritis & Rheumatism 65 2013 880 889
-
(2013)
Arthritis & Rheumatism
, vol.65
, pp. 880-889
-
-
Genovese, M.C.1
Bojin, S.2
Biagini, I.M.3
-
42
-
-
84885186752
-
Lupuzor/P140 peptide in patients with systemic lupus erythematosus: A randomised, double-blind, placebo-controlled phase IIb clinical trial
-
R. Zimmer, H.R. Scherbarth, O.L. Rillo, J.J. Gomez-Reino, and S. Muller Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial Annals of the Rheumatic Diseases 2012
-
(2012)
Annals of the Rheumatic Diseases
-
-
Zimmer, R.1
Scherbarth, H.R.2
Rillo, O.L.3
Gomez-Reino, J.J.4
Muller, S.5
-
43
-
-
79959856423
-
Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial
-
R.F. van Vollenhoven, N. Kinnman, E. Vincent, S. Wax, and J. Bathon Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial Arthritis & Rheumatism 63 2011 1782 1792
-
(2011)
Arthritis & Rheumatism
, vol.63
, pp. 1782-1792
-
-
Van Vollenhoven, R.F.1
Kinnman, N.2
Vincent, E.3
Wax, S.4
Bathon, J.5
-
44
-
-
84856795563
-
Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial
-
E.M. Ginzler, S. Wax, and A. Rajeswaran Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial Arthritis Research & Therapy 14 2012
-
(2012)
Arthritis Research & Therapy
, vol.14
-
-
Ginzler, E.M.1
Wax, S.2
Rajeswaran, A.3
-
45
-
-
44849085476
-
The innate immune system in SLE: Type i interferons and dendritic cells
-
L. Ronnblom, and V. Pascual The innate immune system in SLE: type I interferons and dendritic cells Lupus 17 2008 394 399
-
(2008)
Lupus
, vol.17
, pp. 394-399
-
-
Ronnblom, L.1
Pascual, V.2
-
46
-
-
66449097622
-
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase i trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus
-
Y. Yao, L. Richman, and B.W. Higgs Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus Arthritis & Rheumatism 60 2009 1785 1796
-
(2009)
Arthritis & Rheumatism
, vol.60
, pp. 1785-1796
-
-
Yao, Y.1
Richman, L.2
Higgs, B.W.3
-
47
-
-
80053562466
-
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double-blind randomised study
-
J.T. Merrill, D.J. Wallace, and M. Petri Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study Annals of the Rheumatic Diseases 70 2011 1905 1913
-
(2011)
Annals of the Rheumatic Diseases
, vol.70
, pp. 1905-1913
-
-
Merrill, J.T.1
Wallace, D.J.2
Petri, M.3
-
48
-
-
84875697484
-
Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: A phase i randomized, controlled, dose-escalation study
-
M. Petri, D.J. Wallace, and A. Spindler Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study Arthritis & Rheumatism 65 2013 1011 1021
-
(2013)
Arthritis & Rheumatism
, vol.65
, pp. 1011-1021
-
-
Petri, M.1
Wallace, D.J.2
Spindler, A.3
-
49
-
-
84868144947
-
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study
-
J.M. McBride, J. Jiang, and A.R. Abbas Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study Arthritis & Rheumatism 64 2012 3666 3676
-
(2012)
Arthritis & Rheumatism
, vol.64
, pp. 3666-3676
-
-
McBride, J.M.1
Jiang, J.2
Abbas, A.R.3
-
50
-
-
84873870755
-
Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid
-
B.R. Lauwerys, E. Hachulla, and F. Spertini Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid Arthritis & Rheumatism 65 2013 447 456
-
(2013)
Arthritis & Rheumatism
, vol.65
, pp. 447-456
-
-
Lauwerys, B.R.1
Hachulla, E.2
Spertini, F.3
|